» Articles » PMID: 38459219

Helicobacter Pylori Components Increase the Severity of Metabolic Syndrome and Its Hepatic Manifestations Induced by a High Fat Diet

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 8
PMID 38459219
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolic syndrome, often accompanied by hepatic manifestations, is a high-risk factor for developing cardiovascular disease. Patients with metabolic dysfunction associated with steatohepatic disease (MASDL) are at significant risk of developing coronary artery disease. Atherosclerosis is a systemic inflammatory disorder in which several factors, including dietary or infectious factors, can cause an inflammatory response. Helicobacter pylori (HP) bacteria have been implicated in the progression of proatherogenic vascular endothelial lesions, moreover, our previous study in an experimental in vivo model of Cavia porcellus showed that HP components and high-fat substances acted synergistically in promoting vascular endothelial inflammation, leading to an early onset of a proatherogenic environment. In the present study, our goal was to determine the contribution of HP components to the development of hepatic manifestations of metabolic syndrome in an experimental model. Our results showed that HP infection in animals exposed to a high-fat diet increased oxidative stress and lipid peroxidation, followed by endothelial lipid deposition, impaired endothelial apoptosis, cell lysis, and increased vascular stiffness. Finally, histopathological analysis of liver tissue showed signs of MASLD development in HP-infected animals fed a high-fat diet.

Citing Articles

Potential mechanisms and therapeutic prospects of the association between infection and metabolic dysfunction-associated steatohepatitis.

Gou G, Li T, Liu C, Meng T, Li Y World J Hepatol. 2025; 17(1):101798.

PMID: 39871896 PMC: 11736473. DOI: 10.4254/wjh.v17.i1.101798.

References
1.
Longo-Mbenza B, Nsenga J, Mokondjimobe E, Gombet T, Assori I, Ibara J . Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans. Vasc Health Risk Manag. 2012; 6:455-61. PMC: 3423148. DOI: 10.2147/VHRM.S28680. View

2.
Moludi J, Maleki V, Jafari-Vayghyan H, Vaghef-Mehrabany E, Alizadeh M . Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics. Clin Exp Pharmacol Physiol. 2020; 47(6):927-939. DOI: 10.1111/1440-1681.13250. View

3.
Gajewski A, Gawrysiak M, Krupa A, Rechcinski T, Chalubinski M, Gonciarz W . Accumulation of Deleterious Effects in Gastric Epithelial Cells and Vascular Endothelial Cells In Vitro in the Milieu of Components, 7-Ketocholesterol and Acetylsalicylic Acid. Int J Mol Sci. 2022; 23(11). PMC: 9181086. DOI: 10.3390/ijms23116355. View

4.
Polyzos S, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E . Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2012; 62(1):121-6. DOI: 10.1016/j.metabol.2012.06.007. View

5.
Adachi K, Mishiro T, Toda T, Kano N, Fujihara H, Mishima Y . Effects of eradication on serum lipid levels. J Clin Biochem Nutr. 2018; 62(3):264-269. PMC: 5990401. DOI: 10.3164/jcbn.17-88. View